Does a Blood Pressure Under 130 Lower Dementia Risk?

CRHCP, the China Rural Hypertension Control Project, was built to answer the question earlier trials left open. It randomized 326 villages with hypertension to a nonphysician-led program aiming for under 130/80 or to usual care. Participants started with systolic pressures above 150. Over seven years, new dementia occurred in 8.85% of the intensive group and 10.55% of usual care, a 15% relative reduction. Cognitive impairment short of dementia was 13% less common.

What SPRINT MIND couldn't finish

SPRINT MIND in 2019 randomized 9,361 adults to a systolic target under 120 or under 140. Intensive treatment cut mild cognitive impairment by about a fifth, but on dementia alone the reduction was around 17% and did not reach statistical significance. The trial had stopped early for cardiovascular benefit, so fewer dementia cases had time to accrue. Extended follow-up published in 2025 landed the same way: MCI reduced, dementia alone still short of statistical significance. A 2021 meta-analysis of intensive-versus-standard trials also failed to find a dementia signal. The field was left with a strong hint and no confirmed answer. CRHCP is now that answer, in a population large enough and followed long enough to see the endpoint.

How the trials line up

The harm story flipped

The standard argument against pushing pressure lower is that older, comorbid patients trade fewer heart attacks for more kidney injury, syncope, and dizziness. In SPRINT that tradeoff was real but small: acute kidney injury rose from about 2.5% to 4%, hypotension and syncope each rose by around a percentage point, and injurious falls did not increase. In CRHCP the tradeoff went the other way. Serious adverse events over seven years were 47.15% in the intensive arm and 49.78% in usual care, meaning the treated group had fewer, not more. The likely reason is who was in the trial. Participants started with much higher baseline pressures and were younger and less frail than the SPRINT cohort, so lowering pressure removed more risk than it added.

Who this evidence really fits

The people who stand to gain the most look like the CRHCP population: adults whose systolic runs in the 140s or higher and who aren't frail or in the oldest-old category. Across trials, the bigger the drop in pressure and the higher the starting number, the bigger the dementia risk reduction. In SPRINT, the sharpest cognitive gains showed up in those with the highest baseline risk. The picture changes in the very old and frail. Post hoc SPRINT analyses in frail participants found no cognitive benefit from intensive control, and observational data in the oldest-old have repeatedly shown that pushing already-low pressures lower tracks with faster cognitive decline and higher mortality. Kidney injury, hypotension, and syncope also rise more steeply with age and frailty. So the target isn't one number for everyone. It's under 130 for most adults with real hypertension, and something individualized above that for people who are frail or already run low.

What the guidelines already say, and what's still missing

The 2025 AHA/ACC hypertension guideline, published in August 2025, made a systolic target under 130 mmHg a Class 1 recommendation specifically to prevent mild cognitive impairment and dementia. That is new: the 2017 guideline noted that blood pressure lowering was reasonable but did not set a target for cognitive outcomes. The evidence base under that recommendation has now caught up with it. What's still missing is peer-reviewed publication of the seven-year CRHCP dementia data (it was presented as a Hot Line at ESC 2026), replication in a Western cohort with lower baseline pressures, and a direct comparison of whether pushing to under 120 adds brain benefit over under 130 without adding harm. For most adults with hypertension, intensive control is now one of the very short list of interventions with randomized human evidence for lowering dementia risk, and the guidelines have already moved in that direction.